NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Line of Insulin Receptor Antibodies - The insulin receptor is a transmembrane receptor that belongs to the tyrosine kinase receptors class. It is a heterotetrameric glycoprotein composed of disulfide-linked subunits in a â-á-á-â configuration
AnaSpec Introduces Line of Insulin Receptor Antibodies

 

NewswireTODAY - /newswire/ - San Jose, CA, United States, 2007/05/21 - The insulin receptor is a transmembrane receptor that belongs to the tyrosine kinase receptors class. It is a heterotetrameric glycoprotein composed of disulfide-linked subunits in a â-á-á-â configuration.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This transmembrane receptor consists of 95kDa â-subunit, a single transmembrane domain, and 135kDa á-subunit, which is completely extracellular. Binding of insulin to the receptor results in stimulation of its intrinsic kinase activity. The insulin receptor mediates insulin action through the phosphorylation of substrate proteins. Insulin receptor becomes phosphorylated as a response to stimulation of cells by insulin, insulin-like growth factor (IGF-I) and interleukin 4. The major substrates of the insulin receptor kinase are the insulin receptor substrate (IRS) family of proteins, IRS-1, IRS-2, IRS-3, IRS-4. Recently, two more signaling proteins, IRS5/DOK4 and IRS6/DOK5, have been identified as potentially new members of the IRS family. The insulin receptor substrate-1 (IRS-1), a 170-185 kDa protein, is a major substrate of the insulin receptor. IRS-1 is phosphorylated on serine, threonine and tyrosine residues in a variety of tissues.

AnaSpec offers a line of insulin receptor antibodies that targets researchers working in protein phosphorylation, glucose metabolism, cancer, and diabetes studies. These antibodies are validated on ELISA, and Western Blot or IHC, and offered in research-grade size.

About AnaSpec, Inc.
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry. Established in 1993, AnaSpec's ISO9001:2000 certified headquarters and manufacturing facilities are located in San Jose, CA.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Line of Insulin Receptor Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1
SCHOTT Pharma Unveils Innovative Nest Design for Ready-to-use Cartridges
Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-class MAIT Cell Engager in Immuno-oncology
Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry through Consistent Quality Assurance, On-time Delivery
Bylvay® (odevixibat) Data Shows Sustained Improvement in Severe Itch and Serum Bile Acid Levels in Patients with PFIC and ALGS
Genome BC, STEMCELL Technologies and UBC Partner to Accelerate the Ability to Develop Stem Cells
PathogenDx Applauded by Frost & Sullivan for Enabling Early and Precise UTI Diagnosis with its Microarray Detection Platform
BASF Partners with Acies Bio to Drive Sustainable Production of Personal and Home Care Ingredients
Ipsen’s Kayfanda® (odevixibat) Approved in European Union for Cholestatic Pruritus in Alagille Syndrome, A Rare Liver Disease
STEMCELL Technologies and Axion BioSystems Partner to Streamline Culture and Analysis of Excitable Cells
Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence, Highlighting Agility, Responsiveness, Customer Value
BASF Declares Force Majeure for Selected Vitamin A, Vitamin E, and Carotenoid Products As Well As Selected Aroma Ingredients
Ono Pharmaceutical Co., Ltd Enters into A New Option and Research Collaboration Agreement with Monash University
Aragen Life Sciences Ltd Receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)